Danaher shares tumble after company cuts revenue-growth outlook

Danaher shares fell about 11% on July 21 after the company reduced the upper end of its 2026 core revenue-growth outlook, highlighting weaker demand in parts of its business.

The company now expects core revenue growth of up to 4% in 2026, down from the previous upper limit of 6%. Danaher cited weaker respiratory-testing revenue and softness in biotechnology.

The outlook cut outweighed better-than-expected quarterly earnings and an increased profit forecast. The market reaction showed that investors were more focused on the weaker revenue trajectory and demand conditions than on the earnings beat.

The update matters beyond Danaher because it points to pressure in life-sciences and biotechnology demand. Companies exposed to testing and biotechnology spending could face increased investor scrutiny as markets assess whether the softness is temporary or more persistent.

Confirmed elements include Danaher's quarterly earnings beat, its higher profit forecast, the reduction in the upper end of its core revenue-growth outlook and the roughly 11% decline in its shares. What remains uncertain is how long the weakness in respiratory testing and biotechnology will last and whether demand will improve enough for Danaher to achieve its revised growth expectations.